Retroauricular subperiosteal vs systemic intravenous glucocorticoid administration on efficacy and blood glucose in diabetic patients with sudden deafness

Table 1 The two groups exhibit comparability in baseline data, n (%)

	Observation group (n = 66)	Control group (n = 62)	χ2	P value
Age, years old			0.183	0.669
≤ 60	38 (57.58)	38 (61.29)
> 60	28 (42.42)	24 (38.71)
Sex			0.32	0.572
Male	46 (69.70)	46 (74.19)
Female	20 (30.30)	16 (25.81)
Body mass index, kg/m²			0.183	0.669
≤ 24	28 (42.42)	24 (38.71)
> 24	38 (57.58)	38 (61.29)
Affected ear			0.125	0.724
Left	32 (48.48)	32 (51.61)
Right	34 (51.52)	30 (48.39)
History of smoking			0.847	0.357
With	7 (10.61)	10 (16.13)
Without	59 (89.39)	52 (83.87)
Dizziness			0.484	0.486
With	9 (13.64)	6 (9.68)
Without	57 (86.36)	56 (90.32)
Hypertension			1.002	0.317
With	20 (30.30)	24 (38.71)
Without	46 (69.70)	38 (61.29)
Hyperlipidemia			0.671	0.413
With	14 (21.21)	17 (27.42)
Without	52 (78.79)	45 (72.58)
Course of T2DM, years			0.426	0.514
≤ 5	25 (37.88)	27 (43.55)
> 5	41 (62.12)	35 (56.45)
Residence			0.157	0.692
Urban	55 (83.33)	50 (80.65)
Rural	11 (16.67)	12 (19.35)

T2DM: Type 2 diabetes mellitus.